'Our study shows a greater risk reduction for people who received an mRNA vaccine after having received a first dose of a vector-based, as compared to people having received the vector-based vaccine for both doses,' Nordstrom said.
The researchers found an increased risk of deep vein thrombosis -- a blood clot in the leg -- up to three months after COVID-19 infection, pulmonary embolism -- a blood clot in the lung -- up to six months, and a bleeding event up to two months.